Equity
Vaxcyte, Inc. (PCVX) perpetual futures
PCVX perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PCVXUSDT.
Vaxcyte, Inc. is a clinical-stage biotechnology company developing protein-based vaccines to prevent or manage bacterial infectious diseases, led by its pneumococcal conjugate vaccine candidate VAX-24.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
2/3 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
3 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kThin liquidity · 2 of 2 venues absorb $10k · Typical cost: +59.9 bps – +60.4 bps
Cheapest execution: Bitget · +59.6 bps
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
PCVXTightest spread
PCVXHighest volume
PCVXFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $122.33 |
| 12-month target range (low – high) | $120 – $125 |
| Ratings in the provider's consensus | 11 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 1 | 9 | 1 | 0 | 0 |
| Oct 2026 | 1 | 9 | 1 | 0 | 0 |
| Sep 2026 | 1 | 9 | 1 | 0 | 0 |
| Aug 2026 | 1 | 9 | 1 | 0 | 0 |
| Jul 2026 | 1 | 9 | 1 | 0 | 0 |
| Jun 2026 | 1 | 9 | 1 | 0 | 0 |
| May 2026 | 1 | 9 | 1 | 0 | 0 |
| Apr 2026 | 1 | 9 | 1 | 0 | 0 |
| Mar 2026 | 1 | 9 | 1 | 0 | 0 |
| Feb 2026 | 1 | 9 | 1 | 0 | 0 |
| Jan 2026 | 1 | 9 | 1 | 0 | 0 |
| Dec 2025 | 1 | 7 | 1 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
PCVX-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Vaxcyte officer Harpreet S. Dhaliwal exercised options on 17,000 shares at $24.79 and sold 17,000 shares at $67.33-$68.819 on 2026-11-11. 68,085 shares were held after.
Vaxcyte officer Elvia Cowan exercised 3,000 stock options into 3,000 common shares at $25.92, then sold all 3,000 shares at $60.765–$61.547.
Vaxcyte officer Jim Wassil exercised 2,250 stock options at $5.35 and sold the same 2,250 common shares on the open market at $60.779-$61.57, leaving 145,435 shares directly owned.
Vaxcyte officer Jim Wassil exercised options on 18,000 shares at $5.35 and sold 18,000 shares at $86.74, leaving 145,435 shares.
Vaxcyte officer Elvia Cowan exercised options on 19,000 shares at $25.92 and sold 19,000 common shares at $86.74, per a Form 4 filed 2026-10-07.
Vaxcyte officer Jim Wassil exercised 2,250 options at $5.35 and sold 2,250 shares at $56.65-$57.09, leaving 145,435 shares.
CEO Grant Pickering reported a tax-withholding disposition (Form 4, filed 2026-09-09): 17,056 shares of Common Stock withheld at $60.36 to cover taxes, leaving 429,902 shares owned.
Vaxcyte officer Andrew Guggenhime reported a tax-withholding (F-InKind) disposal of 7,155 common shares at $60.36 on 2026-09-08, leaving 95,316 shares owned.
Filings
44 · Latest SEC filingsVaxcyte officer Harpreet S. Dhaliwal exercised options on 17,000 shares at $24.79 and sold 17,000 shares at $67.33-$68.819 on 2026-11-11. 68,085 shares were held after.
Vaxcyte officer Elvia Cowan exercised 3,000 stock options into 3,000 common shares at $25.92, then sold all 3,000 shares at $60.765–$61.547.
Vaxcyte officer Jim Wassil exercised 2,250 stock options at $5.35 and sold the same 2,250 common shares on the open market at $60.779-$61.57, leaving 145,435 shares directly owned.
Vaxcyte officer Jim Wassil exercised options on 18,000 shares at $5.35 and sold 18,000 shares at $86.74, leaving 145,435 shares.
Vaxcyte officer Elvia Cowan exercised options on 19,000 shares at $25.92 and sold 19,000 common shares at $86.74, per a Form 4 filed 2026-10-07.
Vaxcyte officer Jim Wassil exercised 2,250 options at $5.35 and sold 2,250 shares at $56.65-$57.09, leaving 145,435 shares.
Officer Elvia Cowan reported 1,327 shares of Vaxcyte common stock withheld for taxes at $60.36 per share, leaving 27,860 shares held.
Vaxcyte officer Wassil Jim sold 2,715 common shares in two open-market sales at $59.52-$61.16 and had 5,459 shares withheld for taxes at $60.36; he held 145,435 shares afterward.
CEO Grant Pickering reported a tax-withholding disposition (Form 4, filed 2026-09-09): 17,056 shares of Common Stock withheld at $60.36 to cover taxes, leaving 429,902 shares owned.
Vaxcyte officer Dhaliwal Harpreet S. disposed of 7,651 common shares at $60.36 each on 2026-09-08 through F-InKind tax withholding, leaving 68,085 shares owned.
Vaxcyte officer Andrew Guggenhime reported a tax-withholding (F-InKind) disposal of 7,155 common shares at $60.36 on 2026-09-08, leaving 95,316 shares owned.
Vaxcyte officer Luis Jodar received awards: 88,254 stock options at $61.16 and 52,632 common shares. These are compensation grants, not open-market purchases.
Vaxcyte officer Luis Jodar reported holding 23,941 stock options (right to buy) at a $47.30 strike price, per an initial Form 3 filing. No purchase or sale occurred; this is a new holdings disclosure.
Vaxcyte officer Harpreet S. Dhaliwal reported disposing of 1,020 common shares at $60.74-$61.58 via F-Tax withholding in 2 transactions, leaving 75,736 shares owned.
Vaxcyte officer Elvia Cowan reported 569 shares of Common Stock withheld (F-Tax) across two transactions at $60.74-$61.58, leaving 29,187 shares owned.
Vaxcyte CEO Grant Pickering disposed of 6,289 common shares across two F-InKind tax-withholding transactions on Aug 31-Sep 2, 2026, at $60.74-$61.58. He held 446,958 shares after.
Vaxcyte officer Andrew Guggenhime (President and CFO) reported disposing of 2,705 common shares on Aug 31 and Sep 2, 2026, at $60.74-$61.58, under F-InKind tax withholding. He held 102,471 shares after.
Vaxcyte COO Jim Wassil exercised 2,250 options at $5.35, then sold 3,477 shares at $60.89–$61.48. He also surrendered 2,705 shares for tax withholding at $60.74–$61.58. He held 153,609 shares after.
Vaxcyte officer Dhaliwal Harpreet S. exercised options on 17,000 shares at $24.79 and sold the same 17,000 shares at $55.004 on 2026-08-05, leaving 76,756 shares owned.
Vaxcyte officer Wassil Jim exercised 2,250 stock options at $5.35 and sold 2,250 common shares at $53.502-$54.089; he held 157,541 shares after.
Vaxcyte officer Andrew Guggenhime exercised 10,000 stock options at $5.35, converting them into 10,000 common shares, then sold 10,000 common shares on the open market at $53.761-$54.178.
Transcripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 21, 2026, 07:33 PM UTC
Company data
Company intelligence
Market cap history
Not comparable with the headline: the provider's history counts about 148.91M shares, the headline 158.3M. Shown as the provider reports it.
Analyst track record
How the analysts covering PCVX have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 50 | 167 |
| Analysts | 15 | 19 |
| Buy / hold / sell | 48 / 2 / 0 | 163 / 4 / 0 |
| Upgrades / downgrades / initiations | 0 / 0 / 0 | 0 / 0 / 6 |
| Price targets hit / missed | 0 / 46 (0%) | 4 / 134 (3%) |
| Avg. return after a rating (TipRanks) | -43.0% | -40.8% |
| Best / worst call | -9.1% / -62.6% | +60.2% / -62.6% |
After buy calls on this stock: median 21-day move +3.2% vs S&P 500 +0.6% (n = 168)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Salim SyedMizuho Securities85% hit rate on this stock · 13 targets measuredBuytarget $163Oct 5, 2026
- Thomas ShraderBTIG53% hit rate on this stock · 15 targets measuredBuytarget $89.00Nov 4, 2026
- Jason GerberryBank of America Securities33% hit rate on this stock · 15 targets measuredBuyno targetNov 5, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 5, 2026 | Jason GerberryBank of America SecuritiesNov 5, 2026 | BuyMaintained | –↗ | article ↗ |
| Nov 5, 2026 | Unknown AnalystLeerink PartnersNov 5, 2026 | BuyMaintained | $102↗ | article ↗ |
| Nov 5, 2026 | Tara BancroftTD CowenNov 5, 2026 | BuyMaintained | $75.00↗ | article ↗ |
| Nov 4, 2026 | Thomas ShraderBTIGNov 4, 2026 | BuyMaintained | $89.00↗ | article ↗ |
| Oct 18, 2026 | Seamus FernandezGuggenheimOct 18, 2026 | BuyReiterated | $125↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 17, 2026 · 50 ratings
Frequently asked questions
Where can I trade PCVX perpetual futures?
Vaxcyte, Inc. (PCVX) perpetual futures trade on 2 crypto venues, including MEXC, Bitget. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade PCVX around the clock?
Yes. Unlike the underlying stock, PCVX perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on PCVX perpetuals?
Right now the PCVX perp funding rate is -6.7% annualized (venue median), ranging from -13.4% to 0.0% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the PCVX perp price compare to the Vaxcyte, Inc. stock?
The venue-median PCVX perp mark is $55.5 versus a reference stock price of $55.5, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a PCVX perpetual future?
A PCVX perpetual is a derivative that tracks the price of Vaxcyte, Inc. with no expiry date. It lets you take long or short exposure to Vaxcyte, Inc. on crypto venues, around the clock.
What is PCVXUSDT perpetual?
PCVXUSDT is the symbol most crypto exchanges use for the Vaxcyte, Inc. perpetual settled in USDT (Tether). It tracks the PCVX share price through an index, trades 24/7 with leverage and never expires.
MEXC
Bitget
BingX